hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)


Phase 3 Results N/A

Summary of Purpose

Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can play a role in preventing recurrent vascular events from ischemic heart disease patients, whose mechanism consists in not only the reduction of serum lipid level but also anti-inflammatory effects. Serum high sensitive CRP is known to be a predictor of cardiovascular events independent of other conventional risk factors. The present...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 22 April 2016.

1 Mar 2004 7 Aug 2006 1 Jul 2014 Unavailable 1 Apr 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Purpose: Prevention
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment


  • Tatsuo Kohriyama, MD, PhD Hiroshima University Hospital Hiroashima, Hiroshima, Japan, 734-8551 Phone: +81-82-257-5201